AbCellera Biologics Inc. (ABCL) Stock

Understand AbCellera Biologics Inc.: how it makes money

AbCellera operates an AI-powered antibody discovery platform that mines natural immune repertoires to find drug candidate antibodies, earning research fees, licensing fees, and milestone and royalty payments from pharma partners. Revenue is deeply lumpy and milestone-driven, so quarterly results swing sharply and the company depends on partners advancing discovered molecules through trials to trigger the next payment.

AbCellera does not sell a product; it licenses antibodies and collects lumpy milestone and royalty payments from partners only when discovered molecules reach pre-specified trial or commercial stages, leaving revenue near zero between readouts.

Business quality (Unprofitable): Unprofitable. Near-zero revenue, a -1550% operating margin, and a pipeline that has yet to produce a commercial sale. Value is entirely in the discovery platform and the optionality of partner-backed assets.

Bull case

• Phase 2 data imminent: ABCL635 could be highly de-risked by positive Phase 2 data expected soon, making it the single most important near-term catalyst for the stock.
• Jazz deal has $2B upside: Jazz could generate over $2 billion in downstream payments plus tiered net-sales royalties, giving AbCellera a clear monetization path that dwarfs its current research-fee income.
• Pipeline deepens into 2027: Management expects ABCL688 and ABCL386 to enter Phase 1/2 studies in 2027, adding two more near-term data catalysts beyond ABCL635 and broadening the platform's proof points.

Bear case

• Placebo could blunt efficacy: A pronounced placebo response could reduce ABCL635's observed treatment effect in Phase 2, meaning a biologically active antibody might still fail to clear the statistical bar.
• One asset exits pipeline: ABCL575 will not advance beyond Phase 1 under current development plans, narrowing the near-term catalyst window to essentially a single molecule heading into its readout.
• Cash burn is extreme: Operating margin of -1550% means AbCellera is spending roughly 16 times its revenue on operations, a burn rate that leaves little room for a prolonged development delay without raising dilutive capital.

AbCellera Biologics Inc. earnings call transcripts

• ABCL Q1 FY26 earnings call transcript (reported 2026-05-11) · analysis

All ABCL earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• ImmunityBio, Inc. (IBRX)
• Kymera Therapeutics, Inc. (KYMR)
• Lifecore Biomedical, Inc. (LFCR)
• CytomX Therapeutics, Inc. (CTMX)
• Assembly Biosciences, Inc. (ASMB)
• Viridian Therapeutics, Inc. (VRDN)
• Eton Pharmaceuticals, Inc. (ETON)
• Rockwell Medical, Inc. (RMTI)